Completed
PHASE3
INTERVENTIONAL
NCT04943068
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women with Hypoactive Sexual Desire Disorder(with or without Decreased Arousal).
Interventions
Name:
Bremelanotide
Type:
DRUG
Description:
Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector.
Name:
Placebo
Type:
DRUG
Description:
Subjects will self-administer a Placebo subcutaneously (SC) via auto-injector.
Primary Outcomes
Measure:
Change from baseline to End of Study in the desire domain from the FSFI
TimeFrame:
Baseline up to End of Study(8weeks)
Description:
Trial Information
NCT ID
NCT04943068
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Kwang Dong Pharmaceutical co., ltd.
Last Updated
December 15, 2025